1. Cheng, T.Y. et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J. Thorac. Oncol. 11, 1653-1671. https://doi.org/10.1016/j.jtho.2016.05.021 (2016).
2. Tsao, M.S., Yoon, J.Y. The eighth TNM classification for lung cancer-What is next? Lung Cancer. 121, 97-98. https://doi.org/10.1016/j.lungcan.2018.04.018 (2018).
3. Molina, J.R. et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594. https://doi.org/10.4065/83.5.584 (2008).
4. Man, J. et al. Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis. Oncol. Lett. 18, 5185-5196. https://doi.org/10.3892/ol.2019.10873 (2019).
5. Mao, Q. et al. Interplay between the lung microbiome and lung cancer. Cancer Lett. 415, 40-48. https://doi.org/10.1016/j.canlet.2017.11.036 (2018).
6. Maddi, A. et al. The microbiome and lung cancer. J. Thorac. Dis. 11, 280–291. https://doi.org/10.21037/jtd.2018.12.88 (2019).
7. Hasegawa, A. et al. Detection and identification of oral anaerobes in intraoperative bronchial fluids of patients with pulmonary carcinoma. Microbiol. Immunol. 58, 375-381. https://doi.org/10.1111/1348-0421.12157 (2014).
8. Lee, S.H. et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer. 102, 89-95. https://doi.org/10.1016/j.lungcan.2016.10.016 (2016).
9. Liu, H.X. et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int. J. Cancer. 142, 769-778. https://doi.org/10.1002/ijc.31098 (2018).
10. Tsay, J.J. et al. Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am. J. Respir. Crit. Care. Med. 198, 1188-1198. https://doi.org/10.1164/rccm.201710-2118OC (2018).
11. Peters, B.A. et al. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemio.l Biomarkers Prev. 28,731-740. https://doi.org/10.1158/1055-9965.EPI-18-0966 (2019).
12. Zhang, W. et al. Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients. J. Cancer. 10, 1651-62. https://doi.org/10.7150/jca.28077 (2019).
13. Wang, K. et al. A preliminary study of microbiota diversity in saliva and bronchoalveolar lavage fluid from patients with primary bronchogenic carcinoma. Med. Sci. Monit. 25, 2819-2834. https://doi.org/10.12659/MSM.915332 (2019).
14. Cheng, C. et al. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl. Lung Cancer Res. 9, 693-704. https://doi.org/10.21037/tlcr-19-590 (2020).
15. Zhuo, M. et al. Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. Front. Oncol. 10,1584. https://doi.org/10.3389/fonc.2020.01584 (2020).
16. Hosgood, H.D. 3rd et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Env.Mol. Mutagen. 55, 643–651. https://doi.org/10.1002/em.21878 (2014).
17. Cameron, S.J.S. et al. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One. 12,e0177062. https://doi.org/10.1371/journal.pone.0177062 (2017).
18. Hosgood, H.D. 3rd et al. The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural china. Environ. Mol. Mutagen. 60, 617-623. https://doi.org/10.1002/em.22291 (2019).
19. Druzhinin, V.G. et al. Taxonomic diversity of sputum microbiome in lung cancer patients and its relationship with chromosomal aberrations in blood lymphocytes. Sci. Rep. 10(1):9681. https://doi.org/10.1038/s41598-020-66654-x (2020).
20. Herbst, R.S. et al. Lung cancer. N. Engl. J. Med. 359, 1367-1380. https:// doi. org/0.1056 /NEJMra0802714 (2008).
21. Ran, Z. et al. [Analysis of Pulmonary Microbial Diversity in Patients with Advanced Lung Cancer Based on High-throughput Sequencing Technology]. Zhongguo Fei Ai Za Zhi. 23,1031-1038. Chinese. https://doi.org/10.3779/j.issn.1009-3419.2020.103.16 (2020).
22. Goldstraw, P. New staging system: how does it affect our practice? J. Clin. Oncol. 31, 984–991. https://doi.org/10.1200/JCO.2012.42.7922 (2013).
23. Caporaso, J.G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods, 7, 335–336. https://doi.org/10.1038/nmeth.f.303 (2010).
24. Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol., 37, 852–857. https://doi.org/10.1038/s41587-019-0209-9 (2019).
25. Sorenson, T. A method of establishing groups of equal amplitudes in plant sociology based on similarity of species content and its application to analyses of the vegetation on Danish Commons. Biologiske Skrifter, 5, 1–34. (1948).
26. Huang D, et al. The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am. J. Cancer Res. 9, 2047-2063. (2019).
27. Sommariva, M. et al. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell Mol. Life Sci. 77, 2739-2749. https://doi.org/10.1007/s00018-020-03452-8 (2020).
28. Greathouse, K.L, et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 19, 123. https://doi.org/0.1186/s13059-018-1501-6 (2018).
29. Xu, N. et al. (2020) Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. Transl. Lung Cancer Res., 9, 1554-1568. https://doi.org/10.21037/tlcr-20-156 (2020).
30. Segal, L.N. et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat .Microbiol. 1, 16031. https://doi.org/10. 1038/ nmicrobiol .2016.31 (2016).
31. Leng, Q. et al. Microbiota Biomarkers for Lung Cancer. Diagnostics (Basel). 11, 407. https://doi.org/10.3390/diagnostics11030407 (2021).
32. Bello, S. et al. Core Microbiota in Central Lung Cancer With Streptococcal Enrichment as a Possible Diagnostic Marker. Arch. Bronconeumol. (Engl Ed). 20, 30192-30197. English, Spanish. https://doi.org/10.1016/j.arbres.2020.05.034 (2020).
33. Morris, A. et al. Microbiome Project. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 187, 1067-75. https://doi.org/10.1164/rccm.201210-1913OC (2013).
34. Haldar, K. et al. The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir. Res. 21,183. https://doi.org/10.1186/s12931-020-01448-3 (2020).
35. Kumar, R. et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog.13, e1006440. https://doi.org/10.1371/journal.ppat.1006440 (2017).
36. Manning, S.D. Molecular epidemiology of Streptococcus agalactiae (group B Streptococcus). Front. Biosci. 8, s1-18. https://doi.org/10.2741/985 (2003).
37. Furfaro, L.L. et al. Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets. Clin. Microbial. Rev. 31, e00049-18. https://doi.org/10.1128/CMR.00049-18 (2018).
38. Pimentel, B.A. et al. Streptococcus agalactiae infection in cancer patients: a five-year study. European journal of clinical microbiology & infectious diseases. 35, 927-933. https://doi.org/10.1007/s10096-016-2617-9 (2016).
39. Phares, C.R. et al. Active Bacterial Core surveillance/Emerging Infections Program Network. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 299, 2056-2065. https://doi.org/10.1001/jama.299.17.2056 (2008).
40. Farley, M.M. et al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N. Engl. J. Med. 328, 1807-1811. https://doi.org/10.1056/NEJM199306243282503 (1993).
41. Sharma, P. et al. Role of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cells. J. Biol. Chem. 288, 4023-4034. https://doi.org/10.1074/jbc.M112.425728 (2013).
42. Ferreira Eduardo da Costa, A. et al. Reactive oxygen species involved in apoptosis induction of human respiratory epithelial (A549) cells by Streptococcus agalactiae. Microbiology (Reading). 162, 94-99. https://doi.org/10.1099/mic.0.000202 (2013).
43. Oliveira, J.S.S. et al. Reactive oxygen species generation mediated by NADPH oxidase and PI3K/Akt pathways contribute to invasion of Streptococcus agalactiae in human endothelial cells. Mem. Inst. Oswaldo Cruz. 113, e140421. https://doi.org/10.1590/0074-02760170421 (2018).